Yun-Long Zhang Selected Research

Neutralizing Antibodies

1/2020	Blockade of intercellular adhesion molecule-1 prevents angiotensin II-induced hypertension and vascular dysfunction.
1/2018	CXCL1-CXCR2 axis mediates angiotensin II-induced cardiac hypertrophy and remodelling through regulation of monocyte infiltration.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yun-Long Zhang Research Topics

Disease

18	Fibrosis (Cirrhosis) 10/2023 - 01/2014
17	Inflammation (Inflammations) 02/2023 - 03/2016
16	Hypertension (High Blood Pressure) 01/2023 - 03/2016
13	Hypertrophy 01/2022 - 02/2015
12	Cardiomegaly (Heart Hypertrophy) 01/2021 - 02/2015
9	Atrial Fibrillation 01/2023 - 01/2018
7	Heart Diseases (Heart Disease) 10/2023 - 02/2015
6	Heart Failure 01/2022 - 01/2015
5	Neoplasms (Cancer) 01/2024 - 01/2013
5	Atrial Remodeling 01/2023 - 01/2019
5	Cardiovascular Diseases (Cardiovascular Disease) 10/2022 - 01/2018
4	Vascular System Injuries 01/2023 - 03/2016
2	Breast Neoplasms (Breast Cancer) 01/2024 - 10/2009
2	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 10/2023 - 02/2015
2	Cardiac Edema 01/2022 - 01/2021
2	Reperfusion Injury 01/2022 - 12/2019
2	Epilepsy (Aura) 02/2021 - 01/2019
2	Hypertensive Retinopathy 01/2020 - 01/2018
2	Myocardial Infarction 12/2019 - 03/2018
1	Triple Negative Breast Neoplasms 12/2023
1	Pulmonary Arterial Hypertension 01/2023
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2023
1	Hepatocellular Carcinoma (Hepatoma) 01/2023
1	Edema (Dropsy) 01/2022
1	Cardiomyopathies (Cardiomyopathy) 01/2022
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2022
1	Sepsis (Septicemia) 01/2022
1	Mitochondrial Diseases (Mitochondrial Disease) 10/2021
1	Seizures (Absence Seizure) 02/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 10/2020

Drug/Important Bio-Agent (IBA)

20	Angiotensin IIIBA 01/2023 - 01/2014
8	Superoxides (Superoxide)IBA 10/2023 - 01/2018
5	Proteasome Endopeptidase Complex (Proteasome)IBA 10/2023 - 02/2015
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2015
4	SaltsIBA 01/2023 - 01/2018
4	Connexin 43 (Connexin43)IBA 01/2023 - 01/2018
4	CytokinesIBA 02/2022 - 01/2018
4	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020 - 01/2018
3	Desoxycorticosterone (Deoxycorticosterone)IBA 01/2023 - 12/2019
3	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2023 - 01/2019
3	Acetates (Acetic Acid Esters)FDA Link 01/2023 - 12/2019
3	LDN 57444IBA 10/2020 - 01/2020
3	Chemokine ReceptorsIBA 10/2020 - 01/2018
3	SB 225002IBA 10/2020 - 12/2019
3	Gallic AcidIBA 01/2020 - 01/2019
3	VO-OHpicIBA 01/2020 - 01/2019
3	NF-kappa B (NF-kB)IBA 01/2020 - 01/2018
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2024 - 01/2020
2	Therapeutic UsesIBA 10/2023 - 01/2023
2	IntegrinsIBA 02/2023 - 01/2023
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 09/2021
2	Retinaldehyde (Retinal)IBA 10/2022 - 01/2018
2	p38 Mitogen-Activated Protein KinasesIBA 01/2022 - 03/2016
2	AngiotensinsIBA 01/2022 - 03/2016
2	Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA 01/2022 - 01/2021
2	LipidsIBA 10/2021 - 01/2014
2	Deubiquitinating EnzymesIBA 10/2020 - 01/2020
2	TensinsIBA 01/2020 - 01/2018
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2020 - 12/2019
2	Chymotrypsin FDA Link 01/2020 - 01/2020
2	Immunoglobulin G (IgG)IBA 01/2020 - 01/2018
2	Neutralizing AntibodiesIBA 01/2020 - 01/2018
2	Desoxycorticosterone Acetate (DOCA)FDA Link 12/2019 - 01/2018
2	ResveratrolIBA 12/2019 - 01/2019
2	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2019 - 03/2016
2	N- (3,5- bis(trifluoromethyl)phenyl)- 5- chloro- 2- hydroxybenzamideIBA 01/2018 - 01/2018
1	Phenobarbital (Luminal)FDA Link 01/2024
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 12/2023
1	Lipase (Acid Lipase)FDA Link 01/2023
1	Oxidoreductases (Dehydrogenase)IBA 01/2023
1	NADP (NADPH)IBA 01/2023
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2023
1	Clofibric AcidIBA 01/2023
1	Phosphotransferases (Kinase)IBA 01/2023
1	Matrix Metalloproteinases (MMPs)IBA 01/2023
1	Immune Checkpoint InhibitorsIBA 01/2023
1	Interleukin-17 (Interleukin 17)IBA 01/2023
1	Citrate (si)-Synthase (Synthase, Citrate)IBA 01/2022
1	epoxomicinIBA 01/2022
1	cadherin 5IBA 01/2022
1	Fibronectins (Fibronectin)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	ProteomeIBA 01/2022
1	Proteasome InhibitorsIBA 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 10/2021
1	4-phenylbutylamineIBA 10/2021
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 09/2021
1	afliberceptIBA 09/2021
1	gamma-Aminobutyric Acid (GABA)IBA 02/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	Endoplasmic Reticulum Chaperone BiPIBA 01/2021
1	CalcineurinIBA 01/2021
1	Vascular Endothelial Growth Factor CIBA 01/2021
1	Ubiquitin Thiolesterase (Ubiquitin Carboxy-Terminal Hydrolase)IBA 10/2020

Therapy/Procedure

6	Therapeutics 01/2023 - 03/2018
2	Ketogenic Diet 02/2021 - 01/2019
1	Immunotherapy 01/2023
1	Molecular Targeted Therapy 01/2023
1	Ligation 01/2022
1	Punctures 01/2022